Unexpected Deviations and the Role of the QP

Recommendation
17/18 September 2025
Building a Knowledge Framework in GMP
Annex 16 to the EU-GMP Guidelines (Certification by a Qualified Person and Batch Release) states in section 3 that "provided registered specifications (…) are met, a QP may consider confirming compliance or certifying a batch where an unexpected deviation concerning the manufacturing process and/or the analytical control methods from details contained within the MA and/or GMP has occurred". But what exactly are "registered specifications"? And can we deviate from in-process controls?
This is answered in Q&A No 3 to Annex 16 published by EMA "Registered specifications for medicinal products include in-process, bulk and finished product specifications which have been included in the MA application."
However, the criticality of registered in-process specifications "may vary depending on the quality attribute tested, the impact to subsequent manufacturing processes and ability to test the quality attribute in the finished product". So depending on a risk assessment, it might be possible to accept deviations from in-process specifications. As a pre-requisite, the risk assessment performed must confirm that there is "no impact to manufacturing process or product quality".
EMA emphasises that non-compliance with registered product specifications fall outside the scope of Annex 16 section 3. That means that a QP will not be able to certify an affected batch.
What happens, if more than one batch affected by the same unexpected deviation?
In this case, it would be acceptable to certify the batches if they have "already been manufactured and/or tested at the time of discovery of the unexpected deviation".
For batches manufactured after the discovery, these then repeated deviations should be considered to be a change. As a consequence, "variations to the affected marketing authorisations must be submitted". In "exceptional circumstances" and to avoid disruption to supply, it "may be possible to continue QP certification while corrective and preventive action is in progress".
Related GMP News
15.09.2025When Training Falls Short: FDA Findings on GMP Training Deficiencies in 2025
15.09.2025Dealing with Systems without Audit Trail Functionality
15.09.2025Why is RCA (Root Cause Analysis) so important?
10.09.2025The Use of Hoses in Pharmaceutical Production
10.09.2025Revision of EU-GMP Chapter 1 planned with Consultation Phase
10.09.2025Audit Trail Review by the QP / Dealing with a Lack of Justification